ClinicalTrials.gg
TerminatedNCT02101021Updated Jun 29, 2023Results posted

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 3 interventional study of Momelotinib and Placebo to match momelotinib in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Sierra Oncology LLC - a GSK company. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

There will be two phases to this study. The lead-in phase will evaluate the safety, pharmacokinetics, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with nab-paclitaxel and gemcitabine (nab-P + G) in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. The randomized treatment phase will evaluate the efficacy, safety, and tolerability of nab-P + G with either MMB administered at the MTD or placebo in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. Participants will continue study treatment until disease progression, unacceptable toxicity, consent withdrawal, or participant's refusal of treatment. Following treatment, participants will be followed for safety for 30 days and for survival approximately every 3 months for up to 3 years.

02

Conditions studied

  • Metastatic Pancreatic Ductal Adenocarcinoma
03

In context

Lead sponsor

Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

First submitted before Sierra Oncology LLC became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Presence of pancreatic adenocarcinoma plus 1 of the following:

    • Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically, OR
    • Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin in conjunction with either:

      • The presence of a mass in the pancreas, OR
      • A history of resected pancreatic adenocarcinoma
  • per v1.1
  • Adequate organ function defined as follows:

    • Total ≤ 1.25 x (ULN); (AST) and alanine transaminase (ALT) ≤ 3 x ULN
    • (ANC) > 1500 cells/mm\^3, > 100,000 cells/mm\^3, > 9 g/dL
    • Serum creatinine \< ULN OR calculated (CrCl) of ≥ 60 ml/min
  • (ECOG ) 0 or 1
  • Modified Glasgow prognostic score (mGPS) of 1 or 2 at Screening (randomized phase only)

Key Exclusion Criteria:

  • or adjuvant chemotherapy or chemoradiotherapy for pancreatic adenocarcinoma
  • Currently or previously treated with biologic, small molecule, immunotherapy, chemotherapy, or other agents for metastatic pancreatic carcinoma
  • Major surgery within 28 days of first dose of study drug
  • Minor surgical procedure(s) within 7 days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ≥ 1 day before enrollment is acceptable)
  • Known positive status for
  • Chronic active or acute viral hepatitis A, B, or C infection (testing required for and C), or hepatitis B or C carrier
  • Peripheral neuropathy ≥ Grade 2
  • Known or suspected brain or central nervous system metastases
  • Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinoma
  • History of interstitial pneumonitis and/or require supplemental oxygen therapy
  • External biliary drain
  • Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of enrollment

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Momelotinib

    Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.

    Drug: Momelotinib · Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Placebo comparator
    Placebo

    Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.

    Drug: Placebo to match momelotinib · Drug: Nab-paclitaxel · Drug: Gemcitabine

Interventions

  • Tablet (s) administered orally once or twice daily

    Also known as: GS-0387, CYT387

  • DrugPlacebo to match momelotinib

    Placebo to match momelotinib tablets administered orally once or twice daily

  • Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle

  • Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle

06

What researchers measure

Primary outcomes

  1. Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events

    Dose limiting toxicities were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Dose limiting toxicities referred to toxicities experienced during the first 28 days (Cycle 1) of treatment that were judged to be clinically significant and related to study treatment. No statistical analysis was planned or performed for this endpoint.

    Time frame: Up to 28 Days

  2. Randomized Treatment Phase: Overall Survival (OS)

    Overall survival was defined as the time interval from first dose date of MMB to death from any cause

    Time frame: Baseline up to the Date of Death or Censoring, up to 3 years

Secondary outcomes

  1. Lead-In Phase: Overall Survival (OS)

    Overall survival was defined as the time interval from first dose date of MMB to death from any cause

    Time frame: Baseline up to the Date of Death or Censoring, up to 3 years

  2. Lead-In Phase: Progression-Free Survival (PFS)

    Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression is progression based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1. Data from survival, non-progressing participants will be censored at the earliest of the time of initiation of anti-tumor therapy other than the study treatment or the last time that lack of definitive disease progression was objectively documented while on study.

    Time frame: Baseline up to the Date of Event or Censoring, up to 3 years

  3. Lead-In Phase: Overall Response Rate (ORR)

    The ORR was defined as the proportion of participants who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR) as assessed by RECIST v1.1.

    Time frame: Baseline up to the Last Tumor Assessment Date, up to 3 years

  4. Randomized Treatment Phase: Progression-Free Survival (PFS)

    Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause

    Time frame: Baseline up to the Date of Event or Censoring, up to 3 years

  5. Randomized Treatment Phase: Overall Response Rate

    The ORR was defined as the proportion of subjects who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR)

    Time frame: Baseline up to the Last Tumor Assessment Date, up to 3 years

07

Results

Posted May 9, 2018

Participant flow

Participants were enrolled at study sites in the United States (US). The first participant was screened on 02 June 2014. The last study visit occurred on 10 April 2017.

Participant flow — Overall Study
MilestoneMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
Started74734
Completed00000
Not completed74734
Withdrew: Death43603
Withdrew: Withdrew consent from study11020
Withdrew: Lost to follow-up10000
Withdrew: Study terminated by sponsor10111

Outcome measures

PrimaryLead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events

Dose limiting toxicities were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Dose limiting toxicities referred to toxicities experienced during the first 28 days (Cycle 1) of treatment that were judged to be clinically significant and related to study treatment. No statistical analysis was planned or performed for this endpoint.

Time frame:
Up to 28 Days
Reported as:
Number · percentage of participants
Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events
percentage of participantsMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events16.7016.700
PrimaryRandomized Treatment Phase: Overall Survival (OS)

Overall survival was defined as the time interval from first dose date of MMB to death from any cause

Time frame:
Baseline up to the Date of Death or Censoring, up to 3 years

No measurements were reported for this outcome.

SecondaryLead-In Phase: Overall Survival (OS)

Overall survival was defined as the time interval from first dose date of MMB to death from any cause

Time frame:
Baseline up to the Date of Death or Censoring, up to 3 years
Reported as:
Median · Months
Lead-In Phase: Overall Survival (OS)
MonthsMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
Lead-In Phase: Overall Survival (OS)12.4 (3.9 to 22.2)5.1 (3.7 to 11.3)8.7 (7.3 to 18.3)5.6 (4.8 to 18.1)7.1 (5.9 to 12.0)
SecondaryLead-In Phase: Progression-Free Survival (PFS)

Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression is progression based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1. Data from survival, non-progressing participants will be censored at the earliest of the time of initiation of anti-tumor therapy other than the study treatment or the last time that lack of definitive disease progression was objectively documented while on study.

Time frame:
Baseline up to the Date of Event or Censoring, up to 3 years
Reported as:
Median · Months
Lead-In Phase: Progression-Free Survival (PFS)
MonthsMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
Lead-In Phase: Progression-Free Survival (PFS)5.3 (1.4 to 7.4)3.2 (1.9 to 4.8)5.5 (5.3 to 7.2)5.3 (0.0 to 13.0)5.5 (4.5 to 10.1)
SecondaryLead-In Phase: Overall Response Rate (ORR)

The ORR was defined as the proportion of participants who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR) as assessed by RECIST v1.1.

Time frame:
Baseline up to the Last Tumor Assessment Date, up to 3 years
Reported as:
Count of participants · Participants
Lead-In Phase: Overall Response Rate (ORR)
ParticipantsMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
Complete Response (CR)21310
Partial Response (PR)22414
SecondaryRandomized Treatment Phase: Progression-Free Survival (PFS)

Progression-free survival was defined as the time interval from the first dose of MMB to the earlier of the first documentation of definitive disease progression or death from any cause

Time frame:
Baseline up to the Date of Event or Censoring, up to 3 years

No measurements were reported for this outcome.

SecondaryRandomized Treatment Phase: Overall Response Rate

The ORR was defined as the proportion of subjects who achieved a best overall response (BOR) during MMB therapy of complete response (CR) or partial response (PR)

Time frame:
Baseline up to the Last Tumor Assessment Date, up to 3 years

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to the last dose date plus 30 days (maximum exposure= 63.7 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MMB Dose Level 14/7 (57.1%)4/7 (57.1%)7/7 (100%)
MMB Dose Level 23/4 (75%)3/7 (42.9%)4/4 (100%)
MMB Dose Level 36/7 (85.7%)5/7 (71.4%)7/7 (100%)
MMB Dose Level 40/3 (0%)2/3 (66.7%)3/3 (100%)
MMB Dose Level 53/4 (75%)4/4 (100%)4/4 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
PneumoniaInfections and infestations1/70/73/70/31/4
NeutropeniaBlood and lymphatic system disorders0/70/71/71/30/4
HaematemesisGastrointestinal disorders0/70/70/71/30/4
PyrexiaGeneral disorders1/70/71/71/31/4
PolyneuropathyNervous system disorders0/70/70/71/30/4
SepsisInfections and infestations0/70/72/70/30/4
Chest painGeneral disorders0/70/70/70/31/4
Generalised oedemaGeneral disorders0/70/70/70/31/4
Mucosal inflammationGeneral disorders0/70/70/70/31/4
Bile duct obstructionHepatobiliary disorders0/70/70/70/31/4
Most frequent other events
Showing 10 of 194
Most frequent other events
EventMMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5
DiarrhoeaGastrointestinal disorders3/73/43/73/33/4
NauseaGastrointestinal disorders5/74/44/73/33/4
FatigueGeneral disorders5/73/46/72/34/4
AnaemiaBlood and lymphatic system disorders6/72/44/72/33/4
NeutropeniaBlood and lymphatic system disorders0/71/41/72/33/4
Abdominal painGastrointestinal disorders2/71/43/71/33/4
ConstipationGastrointestinal disorders2/73/43/72/33/4
VomitingGastrointestinal disorders3/73/44/70/33/4
Oedema peripheralGeneral disorders4/71/42/72/33/4
PyrexiaGeneral disorders3/72/43/71/33/4

Baseline characteristics

All Enrolled Analysis Set: all participants who received a study participant identification number in the study after screening.

Age, Continuous
Age, Continuous(years)MMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5Total
Mean59.9 ± 12.3263.5 ± 12.1264.7 ± 8.7952.0 ± 5.0059.0 ± 9.1360.7 ± 10.21
Sex: Female, Male
Sex: Female, Male(Participants)MMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5Total
Female232018
Male5153317
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5Total
Asian001001
White6363422
Other110002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5Total
Hispanic or Latino100001
Not Hispanic or Latino6473424
Region of Enrollment
Region of Enrollment(Participants)MMB Dose Level 1MMB Dose Level 2MMB Dose Level 3MMB Dose Level 4MMB Dose Level 5Total
United States7473425
08

Study locations

4 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Indiana University Health Goshen Center for Cancer Care
    Goshen, Indiana 46506, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Apr 2017, 34 months.

Results were first posted in May 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2014
First posted
Apr 1, 2014
StartActual
Jun 2, 2014
Primary completionActual
Apr 10, 2017
CompletionActual
Apr 10, 2017
Results first posted
May 9, 2018
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02101021
Responsible party
Sponsor
First posted
Apr 1, 2014
Start date
Jun 2, 2014
Primary completion
Apr 10, 2017
Completion
Apr 10, 2017
Results posted
May 9, 2018
Last update
Jun 29, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion